Moe Thuzar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Moe Thuzar has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Michael Stowasser
Endocrine Hypertension Research Centre, University of Queensland Frazer Institute, Princess Alexandra Hospital, Brisbane, Australia (M.S.).
6 shared publications - Ken K. Y. Ho
Garvan Institute of Medical Research, St. Vincent’s Hospital and the UNSW Sydney, Sydney, Australia
4 shared publications Michael Stowasser
Endocrine Hypertension Research Centre University of Queensland Frazer Institute Brisbane Australia
4 shared publicationsBrett C McWhinney
Department of Chemical Pathology, Pathology Queensland , Brisbane
3 shared publicationsDiane Cowley
University of Queensland Frazer Institute, Princess Alexandra and Greenslopes Hospitals, Brisbane, Australia (M. Stowasser, D.C., M.T.).
3 shared publications- Jun Yang
Department of Medicine, Monash University, Clayton, Victoria, Australia (J.Y.).
3 shared publications
Latest Publications
- 1 November 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (11)
Standardizing the Seated Saline Suppression Test for Primary Aldosteronism
BACKGROUND: Primary aldosteronism is the most common secondary endocrine form of hypertension. Specific treatment directly against aldosterone excess improves control of (and may cure) hypertension and reduces long-term cardiovascular and renal morbidity in patients with primary aldosteronism. Optimal treatment is guided by the results of adrenal venous sampling, with unilateral adrenalectomy being the preferred management for those with lateralizing forms and medical treatment with a mineralocorticoid antagonist for those with bilateral forms. Seated saline suppression testing, being highly specific for primary aldosteronism, provides a means of confirming the diagnosis and, being highly sensitive for lateralizing primary aldosteronism, allows selection of patients most likely to benefit from adrenal venous sampling and spares those with a negative seated saline suppression testing from having to undergo this invasive and expensive procedure. Recent studies, however, have reported poor performance of the seated saline suppression testing, probably in part due to deviation from published procedural methodology, including inappropriate patient selection, failure to render patients’ potassium replete by the time of the test, or failure to commence the saline infusion on time. METHODS, RESULTS, AND CONCLUSIONS: This has prompted the development of a clear and comprehensive standard operating protocol for seated saline suppression testing so that high-quality test results can be more readily attained and usefully applied both for interpreting research studies and for clinical decision-making.
- 1 November 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (11)
Standardizing the Seated Saline Suppression Test for Primary Aldosteronism
BACKGROUND: Primary aldosteronism is the most common secondary endocrine form of hypertension. Specific treatment directly against aldosterone excess improves control of (and may cure) hypertension and reduces long-term cardiovascular and renal morbidity in patients with primary aldosteronism. Optimal treatment is guided by the results of adrenal venous sampling, with unilateral adrenalectomy being the preferred management for those with lateralizing forms and medical treatment with a mineralocorticoid antagonist for those with bilateral forms. Seated saline suppression testing, being highly specific for primary aldosteronism, provides a means of confirming the diagnosis and, being highly sensitive for lateralizing primary aldosteronism, allows selection of patients most likely to benefit from adrenal venous sampling and spares those with a negative seated saline suppression testing from having to undergo this invasive and expensive procedure. Recent studies, however, have reported poor performance of the seated saline suppression testing, probably in part due to deviation from published procedural methodology, including inappropriate patient selection, failure to render patients’ potassium replete by the time of the test, or failure to commence the saline infusion on time. METHODS, RESULTS, AND CONCLUSIONS: This has prompted the development of a clear and comprehensive standard operating protocol for seated saline suppression testing so that high-quality test results can be more readily attained and usefully applied both for interpreting research studies and for clinical decision-making.
- 26 August 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Urinary Aldosterone Analysed by LC-MS/MS vs Immunoassay for Diagnosis of Primary Aldosteronism
Context: The performance of 24-hour urinary aldosterone (24hr-UAldo) analysed by liquid chromatography-mass spectrometry (LC-MS/MS) (24hr-UAldo-LCMS) for diagnosis of primary aldosteronism (PA) is not established. Objective: To assess the diagnostic performance of 24hr-UAldo-LCMS, vs that measured by immunoassay (24hr-UAldo-IA), for diagnosing PA. Design, Setting and Patients: A cohort study involving 182 prospectively-collected 24hr-urine samples from 167 patients who had hypertension with elevated plasma aldosterone-renin ratio and/or adrenalectomy for unilateral PA, 24-hour urinary sodium (24hr-UNa) measured and seated saline suppression test (SSST) performed, off interfering medications and on unrestricted dietary sodium, over a 5-year period at a tertiary centre. Interventions and Main Outcome Measures: 24hr-UAldo-LCMS was analysed in 182 samples and 24hr-UAldo-IA concurrently in a subset of 121 stored samples. Receiver operating characteristic curve analyses were performed to assess performance of 24hr-UAldo at various 24hr-UNa for diagnosing PA using SSST as the reference test. Results: Mean ± SD 24hr-UAldo-LCMS was higher in cases with positive SSST (n = 127) vs those with negative SSST (n = 55) (50.6 ± 35.7 vs 20.8 ± 13.9 nmol/24 h; P < 0.05). 24hr-UAldo-LCMS ≥23.5 nmol/24 h had 92.1% sensitivity and 82.6% specificity (area under the curve [AUC] = 0.946), while a higher cut-off of ≥27.5 nmol/24 h provided a higher specificity (92.3%) with 78.9% sensitivity to identify PA in those with 24hr-UNa ≥190 mmol/24 h, the 24hr-UNa level with optimal 24hr-UAldo performance. The specificity of 24hr-UAldo-IA was inferior: 66.7% (92.3% sensitivity) at 24hr-UAldo-IA ≥24.5 nmol/24 h (AUC=0.81) and 77.8% (73% sensitivity) at 24hr-UAldo-IA ≥35.5 nmol/24 h, when 24hr-UNa ≥190 mmol/24 h. Conclusion: 24hr-UAldo-LCMS in the setting of 24hr-UNa ≥190 mmol/24 h can diagnose PA with high sensitivity and specificity, at lower cut-offs than 24hr-UAldo-IA
- 26 August 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Urinary Aldosterone Analysed by LC-MS/MS vs Immunoassay for Diagnosis of Primary Aldosteronism
Context: The performance of 24-hour urinary aldosterone (24hr-UAldo) analysed by liquid chromatography-mass spectrometry (LC-MS/MS) (24hr-UAldo-LCMS) for diagnosis of primary aldosteronism (PA) is not established. Objective: To assess the diagnostic performance of 24hr-UAldo-LCMS, vs that measured by immunoassay (24hr-UAldo-IA), for diagnosing PA. Design, Setting and Patients: A cohort study involving 182 prospectively-collected 24hr-urine samples from 167 patients who had hypertension with elevated plasma aldosterone-renin ratio and/or adrenalectomy for unilateral PA, 24-hour urinary sodium (24hr-UNa) measured and seated saline suppression test (SSST) performed, off interfering medications and on unrestricted dietary sodium, over a 5-year period at a tertiary centre. Interventions and Main Outcome Measures: 24hr-UAldo-LCMS was analysed in 182 samples and 24hr-UAldo-IA concurrently in a subset of 121 stored samples. Receiver operating characteristic curve analyses were performed to assess performance of 24hr-UAldo at various 24hr-UNa for diagnosing PA using SSST as the reference test. Results: Mean ± SD 24hr-UAldo-LCMS was higher in cases with positive SSST (n = 127) vs those with negative SSST (n = 55) (50.6 ± 35.7 vs 20.8 ± 13.9 nmol/24 h; P < 0.05). 24hr-UAldo-LCMS ≥23.5 nmol/24 h had 92.1% sensitivity and 82.6% specificity (area under the curve [AUC] = 0.946), while a higher cut-off of ≥27.5 nmol/24 h provided a higher specificity (92.3%) with 78.9% sensitivity to identify PA in those with 24hr-UNa ≥190 mmol/24 h, the 24hr-UNa level with optimal 24hr-UAldo performance. The specificity of 24hr-UAldo-IA was inferior: 66.7% (92.3% sensitivity) at 24hr-UAldo-IA ≥24.5 nmol/24 h (AUC=0.81) and 77.8% (73% sensitivity) at 24hr-UAldo-IA ≥35.5 nmol/24 h, when 24hr-UNa ≥190 mmol/24 h. Conclusion: 24hr-UAldo-LCMS in the setting of 24hr-UNa ≥190 mmol/24 h can diagnose PA with high sensitivity and specificity, at lower cut-offs than 24hr-UAldo-IA
- Open Access
- 3 October 2024
- Published by Wiley in Clinical Endocrinology
- Vol. 102 (1) , 31-43
Adrenal Vein Sampling for Primary Aldosteronism: Recommendations From the Australian and New Zealand Working Group
Adrenal vein sampling (AVS) is the current recommended procedure for identifying unilateral subtypes of primary aldosteronism (PA), which are amenable to surgery with the potential for cure. AVS is a technically challenging procedure usually undertaken by interventional radiologists at tertiary centres. However, there are numerous variations in AVS protocols relating to patient preparation, sampling techniques and interpretation which may impact the success of AVS and patient care. To reduce practice variations, improve the success rates of AVS and optimise patient outcomes, we established an Australian and New Zealand AVS Working Group and developed evidence‐based expert consensus recommendations for the preparation, performance and interpretation of AVS. These recommendations can be used by all healthcare professionals in a multidisciplinary team who look after the diagnosis and management of PA.
- 3 October 2024
- Published by Wiley in Clinical Endocrinology
- Vol. 102 (1) , 31-43
Open AccessAdrenal Vein Sampling for Primary Aldosteronism: Recommendations From the Australian and New Zealand Working Group
Adrenal vein sampling (AVS) is the current recommended procedure for identifying unilateral subtypes of primary aldosteronism (PA), which are amenable to surgery with the potential for cure. AVS is a technically challenging procedure usually undertaken by interventional radiologists at tertiary centres. However, there are numerous variations in AVS protocols relating to patient preparation, sampling techniques and interpretation which may impact the success of AVS and patient care. To reduce practice variations, improve the success rates of AVS and optimise patient outcomes, we established an Australian and New Zealand AVS Working Group and developed evidence‐based expert consensus recommendations for the preparation, performance and interpretation of AVS. These recommendations can be used by all healthcare professionals in a multidisciplinary team who look after the diagnosis and management of PA.
- 16 September 2024
- Published by Bioscientifica in Journal of Endocrinology
- Vol. 263 (2)
The mineralocorticoid system, cardiometabolic health and its interplay with adipose tissue
The mineralocorticoid system, comprising the renin-angiotensin-aldosterone system (RAAS) and associated receptors, is traditionally viewed as a regulator of sodium and fluid balance and blood pressure (BP), with the main mineralocorticoid hormone aldosterone acting via the mineralocorticoid receptor (MR) in distal renal tubules. Over the past few decades, there has been a wider understanding of the role of the mineralocorticoid system in regulating both classical BP-dependent and non-BP-dependent systemic effects. Mounting evidence indicates the novel role of the mineralocorticoid system in cardiometabolic health, with excess mineralocorticoid system activity being associated with adiposity, diabetes, insulin resistance and cardiovascular diseases independent of its effect on BP, and RAAS blockade and MR antagonists offering protection against cardiometabolic dysfunction. The metabolic manifestations of mineralocorticoid system overactivation are mainly mediated by their interactions with adipose tissue, which orchestrates energy, lipids, and glucose homeostasis via effects on the functions of brown and white adipocytes and immune cells. Adipose tissue can, in turn, influence mineralocorticoid system activity by harboring its own RAAS system and by releasing mineralocorticoid-secretory factors/adipokines, resulting in further progression of cardiometabolic dysfunction. This article discusses the interplay between the mineralocorticoid system and adipose tissue in the pathophysiology of cardiometabolic diseases.
- 16 September 2024
- Published by Bioscientifica in Journal of Endocrinology
- Vol. 263 (2)
The mineralocorticoid system, cardiometabolic health and its interplay with adipose tissue
The mineralocorticoid system, comprising the renin-angiotensin-aldosterone system (RAAS) and associated receptors, is traditionally viewed as a regulator of sodium and fluid balance and blood pressure (BP), with the main mineralocorticoid hormone aldosterone acting via the mineralocorticoid receptor (MR) in distal renal tubules. Over the past few decades, there has been a wider understanding of the role of the mineralocorticoid system in regulating both classical BP-dependent and non-BP-dependent systemic effects. Mounting evidence indicates the novel role of the mineralocorticoid system in cardiometabolic health, with excess mineralocorticoid system activity being associated with adiposity, diabetes, insulin resistance and cardiovascular diseases independent of its effect on BP, and RAAS blockade and MR antagonists offering protection against cardiometabolic dysfunction. The metabolic manifestations of mineralocorticoid system overactivation are mainly mediated by their interactions with adipose tissue, which orchestrates energy, lipids, and glucose homeostasis via effects on the functions of brown and white adipocytes and immune cells. Adipose tissue can, in turn, influence mineralocorticoid system activity by harboring its own RAAS system and by releasing mineralocorticoid-secretory factors/adipokines, resulting in further progression of cardiometabolic dysfunction. This article discusses the interplay between the mineralocorticoid system and adipose tissue in the pathophysiology of cardiometabolic diseases.
- Open Access
- 27 October 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1295655
Editorial: Adrenal neuroendocrine system and cardiometabolic health: pathophysiology and clinical implications
Editorial: Adrenal neuroendocrine system and cardiometabolic health: pathophysiology and clinical implications
- 27 October 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1295655
Open AccessEditorial: Adrenal neuroendocrine system and cardiometabolic health: pathophysiology and clinical implications
Editorial: Adrenal neuroendocrine system and cardiometabolic health: pathophysiology and clinical implications
- Open Access
- 20 December 2022
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 68 (5) , 2123-2139
High-Intensity Interval Training is Safe, Feasible and Efficacious in Nonalcoholic Steatohepatitis: A Randomized Controlled Trial
Background High-Intensity Interval Training (HIIT) involves bursts of high-intensity exercise interspersed with lower-intensity exercise recovery. HIIT may benefit cardiometabolic health in people with nonalcoholic steatohepatitis (NASH). Aims We aimed to examine the safety, feasibility, and efficacy of 12-weeks of supervised HIIT compared with a sham-exercise control (CON) for improving aerobic fitness and peripheral insulin sensitivity in biopsy-proven NASH. Methods Participants based in the community [(n = 14, 56 ± 10 years, BMI 39.2 ± 6.7 kg/m2, 64% male), NAFLD Activity Score 5 (range 3–7)] were randomized to 12-weeks of supervised HIIT (n = 8, 4 × 4 min at 85–95% maximal heart rate, interspersed with 3 min active recovery; 3 days/week) or CON (n = 6, stretching; 3 days/week). Safety (adverse events) and feasibility determined as ≥ 70% program completion and ≥ 70% global adherence (including session attendance, interval intensity adherence, and duration adherence) were assessed. Changes in cardiorespiratory fitness (V̇O2peak), exercise capacity (time-on-test) and peripheral insulin sensitivity (euglycemic hyperinsulinemic clamp) were assessed. Data were analysed using ANCOVA with baseline value as the covariate. Results There were no HIIT-related adverse events and HIIT was globally feasible [program completion 75%, global adherence 100% (including adherence to session 95.4 ± 7.3%, interval intensity 95.3 ± 6.0% and duration 96.8 ± 2.4%)]. A large between-group effect was observed for exercise capacity [mean difference 134.2 s (95% CI 19.8, 248.6 s), ƞ2 0.44, p = 0.03], improving in HIIT (106.2 ± 97.5 s) but not CON (− 33.4 ± 43.3 s), and for peripheral insulin sensitivity [mean difference 3.4 mg/KgLegFFM/min (95% CI 0.9,6.8 mg/KgLegFFM/min), ƞ2 0.32, p = 0.046], improving in HIIT (1.0 ± 0.8 mg/KgLegFFM/min) but not CON (− 3.1 ± 1.2 mg/KgLegFFM/min). Conclusions HIIT is safe, feasible and efficacious for improving exercise capacity and peripheral insulin sensitivity in people with NASH. Clinical Trial Registration Number Australian New Zealand Clinical Trial Registry (anzctr.org.au) identifier ACTRN12616000305426 (09/03/2016). Graphical Abstract
- 20 December 2022
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 68 (5) , 2123-2139
Open AccessHigh-Intensity Interval Training is Safe, Feasible and Efficacious in Nonalcoholic Steatohepatitis: A Randomized Controlled Trial
Background High-Intensity Interval Training (HIIT) involves bursts of high-intensity exercise interspersed with lower-intensity exercise recovery. HIIT may benefit cardiometabolic health in people with nonalcoholic steatohepatitis (NASH). Aims We aimed to examine the safety, feasibility, and efficacy of 12-weeks of supervised HIIT compared with a sham-exercise control (CON) for improving aerobic fitness and peripheral insulin sensitivity in biopsy-proven NASH. Methods Participants based in the community [(n = 14, 56 ± 10 years, BMI 39.2 ± 6.7 kg/m2, 64% male), NAFLD Activity Score 5 (range 3–7)] were randomized to 12-weeks of supervised HIIT (n = 8, 4 × 4 min at 85–95% maximal heart rate, interspersed with 3 min active recovery; 3 days/week) or CON (n = 6, stretching; 3 days/week). Safety (adverse events) and feasibility determined as ≥ 70% program completion and ≥ 70% global adherence (including session attendance, interval intensity adherence, and duration adherence) were assessed. Changes in cardiorespiratory fitness (V̇O2peak), exercise capacity (time-on-test) and peripheral insulin sensitivity (euglycemic hyperinsulinemic clamp) were assessed. Data were analysed using ANCOVA with baseline value as the covariate. Results There were no HIIT-related adverse events and HIIT was globally feasible [program completion 75%, global adherence 100% (including adherence to session 95.4 ± 7.3%, interval intensity 95.3 ± 6.0% and duration 96.8 ± 2.4%)]. A large between-group effect was observed for exercise capacity [mean difference 134.2 s (95% CI 19.8, 248.6 s), ƞ2 0.44, p = 0.03], improving in HIIT (106.2 ± 97.5 s) but not CON (− 33.4 ± 43.3 s), and for peripheral insulin sensitivity [mean difference 3.4 mg/KgLegFFM/min (95% CI 0.9,6.8 mg/KgLegFFM/min), ƞ2 0.32, p = 0.046], improving in HIIT (1.0 ± 0.8 mg/KgLegFFM/min) but not CON (− 3.1 ± 1.2 mg/KgLegFFM/min). Conclusions HIIT is safe, feasible and efficacious for improving exercise capacity and peripheral insulin sensitivity in people with NASH. Clinical Trial Registration Number Australian New Zealand Clinical Trial Registry (anzctr.org.au) identifier ACTRN12616000305426 (09/03/2016). Graphical Abstract
- 1 December 2021
- Published by Elsevier in Anaesthesia Critical Care & Pain Medicine
- Vol. 40 (6) , 100947
Obesity, metabolic syndrome, and inflammation: An update for anaesthetists caring for patients with obesity
- 1 December 2021
- Published by Elsevier in Anaesthesia Critical Care & Pain Medicine
- Vol. 40 (6) , 100947
Obesity, metabolic syndrome, and inflammation: An update for anaesthetists caring for patients with obesity
- 1 February 2021
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 35 (2) , 117-123
The mineralocorticoid receptor—an emerging player in metabolic syndrome?
Metabolic syndrome is a cluster of conditions that increase the risk of cardiovascular diseases, and comprises obesity, hypertension, impaired glucose metabolism and dyslipidaemia. It is well recognised that the mineralocorticoid receptor (MR) plays an important role in blood pressure regulation via its effect on salt and water retention in renal tubules, with hypertension being a key feature in primary aldosteronism patients with excess adrenal production of aldosterone, the primary ligand for MRs in the epithelial tissues. MRs are also expressed in a number of non-epithelial tissues including adipose tissue; in these tissues, glucocorticoids or cortisol can also activate MRs due to low levels of 11-beta-hydroxysteroid-dehydrogenase type 2 (11-βHSD2), the enzyme which inactivates cortisol. There is increasing evidence suggesting that over-activation of MRs plays a role in the pathophysiology of the other components of metabolic syndrome, promoting adiposity, inflammation and glucose intolerance, and that MR antagonists may confer beneficial effects on energy and substrate homeostasis and cardiometabolic diseases. This review discusses the advances in the literature shedding light on the MR as an emerging player in metabolic syndrome.
- 1 February 2021
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 35 (2) , 117-123
The mineralocorticoid receptor—an emerging player in metabolic syndrome?
Metabolic syndrome is a cluster of conditions that increase the risk of cardiovascular diseases, and comprises obesity, hypertension, impaired glucose metabolism and dyslipidaemia. It is well recognised that the mineralocorticoid receptor (MR) plays an important role in blood pressure regulation via its effect on salt and water retention in renal tubules, with hypertension being a key feature in primary aldosteronism patients with excess adrenal production of aldosterone, the primary ligand for MRs in the epithelial tissues. MRs are also expressed in a number of non-epithelial tissues including adipose tissue; in these tissues, glucocorticoids or cortisol can also activate MRs due to low levels of 11-beta-hydroxysteroid-dehydrogenase type 2 (11-βHSD2), the enzyme which inactivates cortisol. There is increasing evidence suggesting that over-activation of MRs plays a role in the pathophysiology of the other components of metabolic syndrome, promoting adiposity, inflammation and glucose intolerance, and that MR antagonists may confer beneficial effects on energy and substrate homeostasis and cardiometabolic diseases. This review discusses the advances in the literature shedding light on the MR as an emerging player in metabolic syndrome.
- Open Access
- 9 June 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (9) , e3224-e3235
Biochemical, Histopathological, and Genetic Characterization of Posture-Responsive and Unresponsive APAs
Context and Objective Posture-responsive and posture-unresponsive aldosterone-producing adenomas (APAs) account for approximately 40% and 60% of APAs, respectively. Somatic gene mutations have been recently reported to exist in approximately 90% of APAs. This study was designed to characterize the biochemical, histopathologic, and genetic properties of these 2 types of APA. Methods Plasma levels of aldosterone and hybrid steroids (18-oxocortisol and 18-hydroxycortisol) were measured by liquid chromatography-tandem mass spectrometry. Immunohistochemistry for CYP11B2 (aldosterone synthase) and CYP17A1 (17α-hydroxylase) and deoxyribonucleic acid sequencing (Sanger and next-generation sequencing) were performed on APA tissue collected from 23 posture-unresponsive and 17 posture-responsive APA patients. Results Patients with posture-unresponsive APA displayed higher (P < 0.01) levels of hybrid steroids, recumbent aldosterone and cortisol, larger (P < 0.01) zona fasciculata (ZF)-like tumors with higher (P < 0.01) expression of CYP17A1 (but not of CYP11B2) than patients with posture-responsive APA (most of which were not ZF-like). Of 40 studied APAs, 37 (92.5%) were found to harbor aldosterone-driving somatic mutations (KCNJ5 = 14 [35.0%], CACNA1D = 13 [32.5%], ATP1A1 = 8 [20.0%], and ATP2B3 = 2 [5.0%]), including 5 previously unreported mutations (3 in CACNA1D and 2 in ATP1A1). Notably, 64.7% (11/17) of posture-responsive APAs carried CACNA1D mutations, whereas 56.5% (13/23) of posture-unresponsive APAs harbored KCNJ5 mutations. Conclusions The elevated production of hybrid steroids by posture-unresponsive APAs may relate to their ZF-like tumor cell composition, resulting in expression of CYP17A1 (in addition to somatic gene mutation-driven CYP11B2 expression), thereby allowing production of cortisol, which acts as the substrate for CYP11B2-generated hybrid steroids.
- 9 June 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (9) , e3224-e3235
Open AccessBiochemical, Histopathological, and Genetic Characterization of Posture-Responsive and Unresponsive APAs
Context and Objective Posture-responsive and posture-unresponsive aldosterone-producing adenomas (APAs) account for approximately 40% and 60% of APAs, respectively. Somatic gene mutations have been recently reported to exist in approximately 90% of APAs. This study was designed to characterize the biochemical, histopathologic, and genetic properties of these 2 types of APA. Methods Plasma levels of aldosterone and hybrid steroids (18-oxocortisol and 18-hydroxycortisol) were measured by liquid chromatography-tandem mass spectrometry. Immunohistochemistry for CYP11B2 (aldosterone synthase) and CYP17A1 (17α-hydroxylase) and deoxyribonucleic acid sequencing (Sanger and next-generation sequencing) were performed on APA tissue collected from 23 posture-unresponsive and 17 posture-responsive APA patients. Results Patients with posture-unresponsive APA displayed higher (P < 0.01) levels of hybrid steroids, recumbent aldosterone and cortisol, larger (P < 0.01) zona fasciculata (ZF)-like tumors with higher (P < 0.01) expression of CYP17A1 (but not of CYP11B2) than patients with posture-responsive APA (most of which were not ZF-like). Of 40 studied APAs, 37 (92.5%) were found to harbor aldosterone-driving somatic mutations (KCNJ5 = 14 [35.0%], CACNA1D = 13 [32.5%], ATP1A1 = 8 [20.0%], and ATP2B3 = 2 [5.0%]), including 5 previously unreported mutations (3 in CACNA1D and 2 in ATP1A1). Notably, 64.7% (11/17) of posture-responsive APAs carried CACNA1D mutations, whereas 56.5% (13/23) of posture-unresponsive APAs harbored KCNJ5 mutations. Conclusions The elevated production of hybrid steroids by posture-unresponsive APAs may relate to their ZF-like tumor cell composition, resulting in expression of CYP17A1 (in addition to somatic gene mutation-driven CYP11B2 expression), thereby allowing production of cortisol, which acts as the substrate for CYP11B2-generated hybrid steroids.
- 1 May 2020
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 34 (3) , 101400
Controversies and advances in adrenal venous sampling in the diagnostic workup of primary aldosteronism
- 1 May 2020
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 34 (3) , 101400
Controversies and advances in adrenal venous sampling in the diagnostic workup of primary aldosteronism